The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery

被引:15
作者
Kiba, Takayoshi [2 ,3 ]
Inamoto, Takashi [1 ]
Nishimura, Tsutomu [4 ]
Ueno, Masaya [2 ]
Yanagihara, Kazuhiro [2 ]
Teramukai, Satoshi [3 ]
Kato, Hironori [5 ]
Toi, Masakazu [5 ]
Fukushima, Masanori [2 ,3 ]
机构
[1] Tazuke Kofukai Med Res Inst, Kitano Hosp, Dpt Breast Surg, Osaka, Japan
[2] Kyoto Univ Hosp, Outpatient Oncol Unit, Kyoto, Japan
[3] Translat Res Informat Ctr, Kobe, Hyogo, Japan
[4] Kyoto Univ Hosp, Translat Res Ctr, Kyoto, Japan
[5] Kyoto Univ, Grad Sch Med, Dept Breast Surg, Kyoto, Japan
关键词
D O I
10.1186/1471-2407-8-323
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Backgrounds: Prognostic factors are defined as biological or clinical measurement associated with overall survival and/or disease-free survival. Previous studies have shown that patients with estrogen receptor ( ER) positive cancers have a better prognosis than patients whose cancers do not have these receptors. Methods: This study investigated the assessment of variables in defining prognosis of 742 breast cancer women with pathological stage (pTNM) I-III diagnosed between 1980 and 2005 at the Kyoto University Hospital in Japan, by age, clinical stage (cTNM), pTNM, the numbers of positive lymph nodes (pN), and ER status. Results: Multivariate analysis demonstrated that pTNM and ER status were the independent prognostic factors for overall survival, and that pTNM and pN were the independent prognostic factors for disease-free survival. For the 0- to 2-year interval, the hazard of recurrence was higher for the ER-negative patients than the ER-positive patients, and beyond 3 years the hazard was higher for ER-positive patients. Conclusion: The present study confirmed the previous reports which showed favorable prognosis of the patients with lesser pTNM or positive ER status. A reversal of recurrence hazard rate between ER positive and negative breast cancer patients beyond 3 years after operation was detected. The fact may indicate the importance of long term adjuvant hormone therapy for ER positive cancer patients.
引用
收藏
页数:7
相关论文
共 17 条
[1]  
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[2]   DO WE REALLY NEED PROGNOSTIC FACTORS FOR BREAST-CANCER [J].
CLARK, GM .
BREAST CANCER RESEARCH AND TREATMENT, 1994, 30 (02) :117-126
[3]  
DeVita VT., 2001, CANC PRINCIPLES PRAC
[4]   Progress and promise:: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 [J].
Goldhirsch, A. ;
Wood, W. C. ;
Gelber, R. D. ;
Coates, A. S. ;
Thuerlimann, B. ;
Senn, H.-J. ;
Members, Panel .
ANNALS OF ONCOLOGY, 2007, 18 (07) :1133-1144
[5]  
Gospodarowicz M, 2001, CANCER-AM CANCER SOC, V91, P1688, DOI 10.1002/1097-0142(20010415)91:8+<1688::AID-CNCR1184>3.0.CO
[6]  
2-7
[7]   Randomization in substance abuse clinical trials [J].
Hedden, Sarra L. ;
Woolson, Robert F. ;
Malcolm, Robert J. .
SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2006, 1 (1)
[8]  
HORTOBAGYI GN, 1994, P AN M AM SOC CLIN, V23, pA585
[9]  
NOMURA Y, 1992, CANCER, V69, P153, DOI 10.1002/1097-0142(19920101)69:1<153::AID-CNCR2820690127>3.0.CO
[10]  
2-P